Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
12. September 2022 08:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th...
Coherus BioSciences Announces New Employment Inducement Grants
29. August 2022 20:49 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation...
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
04. August 2022 16:01 ET
|
Coherus BioSciences, Inc.
– Commercial launch of CIMERLI™ planned for early October 2022 –– PDUFA date for toripalimab BLA is December 23, 2022 –– Commercial preparation underway for planned July 2023 launch of...
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
02. August 2022 19:15 ET
|
Coherus BioSciences, Inc.
- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales expected in October 2022 - - COLUMBUS AMD...
Coherus BioSciences Announces New Employment Inducement Grants
01. August 2022 23:15 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022, the compensation...
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
28. Juli 2022 16:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
06. Juli 2022 08:00 ET
|
Coherus BioSciences, Inc.
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY,...
Coherus BioSciences Announces New Employment Inducement Grants
22. Juni 2022 16:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022, the compensation committee...
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
11. Mai 2022 18:00 ET
|
Coherus BioSciences, Inc.
- Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May ...
Coherus BioSciences Management to Present at Upcoming Investor Conferences
10. Mai 2022 08:45 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences...